Thomas E. Gwise
41 works · 1,118 citations · h-index 14
Top works
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
- Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
- Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- FDA's Approval of the First Biosimilar to Bevacizumab
- Eligibility criteria and Enrollment of a Diverse Racial and Ethnic population in Multiple Myeloma Clinical Trials
- Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
- Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study
- Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement
- FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease
- Evaluation of Heart Failure Biomarker Tests: A Survey of Statistical Considerations
- Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
- Optimal biased coins for two-arm clinical trials
- Extreme body mass index and survival in newly diagnosed multiple myeloma patients
- Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials
- Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data
- FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity
- Statement on P-values
- An optimal response adaptive biased coin design with k heteroscedastic treatments
- FDA analysis: Impact of BMI on efficacy outcomes in multiple myeloma trials.